Intranasal Immunization with Chlamydial Protease-like Activity Factor and CpG Deoxynucleotides Enhances Protective Immunity Against Genital Chlamydia Muridarum Infection

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2007 Mar 14

PMID 17349723

Citations 37

Authors

Yu Cong

Madhulika Jupelli

M Neal Guentzel

Guangming Zhong

Ashlesh K Murthy

Bernard P Arulanandam

Affiliations

Soon will be listed here.

Abstract

We have reported recently that intranasal (i.n.) vaccination with chlamydial protease-like activity factor (CPAF) and interleukin-12 (IL-12) enhances protective immunity against genital chlamydial challenge. In this study, we show that i.n. or intraperitoneal (i.p.) vaccination with CPAF plus CpG deoxynucleotides (CpG), an alternative T helper 1 (Th1) adjuvant, induced robust CPAF-specific IFN-gamma responses and elevated levels of serum antibody and vaginal IgA production. CPAF+CpG vaccinated animals displayed accelerated genital chlamydial clearance, and minimal hydrosalpinx and inflammatory cellular infiltration compared to mock-immunized (PBS) challenged animals. Together, CpG dexoynucleotides are an efficacious alternative Th1 adjuvant with CPAF to induce protective anti-chlamydial immunity.

Citing Articles

Pathogenic and Protective Roles of Neutrophils in Infection.

Wilton Z, Jamus A, Core S, Frietze K Pathogens. 2025; 14(2).

PMID: 40005489 PMC: 11858174. DOI: 10.3390/pathogens14020112.

Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.

Poston T, Girardi J, Kim M, Zwarycz P, Polson A, Yount K Vaccine. 2024; 43(Pt 1):126526.

PMID: 39536454 PMC: 11817958. DOI: 10.1016/j.vaccine.2024.126526.

Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model.

Broder K, Matrosova V, Tkavc R, Gaidamakova E, Ho L, Macintyre A NPJ Vaccines. 2024; 9(1):207.

PMID: 39528548 PMC: 11554809. DOI: 10.1038/s41541-024-00968-z.

Low-Frequency, Sustained CD4 T-Cell Responses Chlamydia trachomatis in Women: Predominant Targeting of Chlamydial Proteaselike Activity Factor (CPAF).

Li Y, Warren J, Poston T, Clutton G, Shaw F, Conrad S J Infect Dis. 2024; 231(2):e385-e395.

PMID: 39250505 PMC: 11841636. DOI: 10.1093/infdis/jiae443.

Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.

Yount K, Darville T Vaccines (Basel). 2024; 12(8).

PMID: 39203989 PMC: 11359697. DOI: 10.3390/vaccines12080863.

References

Pirbhai M, Dong F, Zhong Y, Pan K, Zhong G . The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells. J Biol Chem. 2006; 281(42):31495-501. DOI: 10.1074/jbc.M602796200. View

Verthelyi D . Adjuvant properties of CpG oligonucleotides in primates. Methods Mol Med. 2006; 127:139-58. DOI: 10.1385/1-59745-168-1:139. View

Murphey C, Murthy A, Meier P, Guentzel M, Zhong G, Arulanandam B . The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol. 2006; 242(2):110-7. PMC: 1885537. DOI: 10.1016/j.cellimm.2006.10.002. View

Murthy A, Chambers J, Meier P, Zhong G, Arulanandam B . Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2006; 75(2):666-76. PMC: 1828486. DOI: 10.1128/IAI.01280-06. View

Weiner G . The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol. 2000; 68(4):455-63. View

Morrison S, Su H, Caldwell H, Morrison R . Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun. 2000; 68(12):6979-87. PMC: 97807. DOI: 10.1128/IAI.68.12.6979-6987.2000. View

Gallichan W, Woolstencroft R, Guarasci T, McCluskie M, Davis H, Rosenthal K . Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001; 166(5):3451-7. DOI: 10.4049/jimmunol.166.5.3451. View

Morrison S, Morrison R . Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun. 2001; 69(4):2643-9. PMC: 98202. DOI: 10.1128/IAI.69.4.2643-2649.2001. View

Zhong G, Fan P, Ji H, Dong F, Huang Y . Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med. 2001; 193(8):935-42. PMC: 2193410. DOI: 10.1084/jem.193.8.935. View

10.

Krieg A . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60. DOI: 10.1146/annurev.immunol.20.100301.064842. View

11.

Moore T, Ananaba G, Bolier J, Bowers S, Belay T, Eko F . Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002; 105(2):213-21. PMC: 1782645. DOI: 10.1046/j.0019-2805.2001.01354.x. View

12.

Morrison R, Caldwell H . Immunity to murine chlamydial genital infection. Infect Immun. 2002; 70(6):2741-51. PMC: 128027. DOI: 10.1128/IAI.70.6.2741-2751.2002. View

13.

Pal S, Davis H, Peterson E, de la Maza L . Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002; 70(9):4812-7. PMC: 128273. DOI: 10.1128/IAI.70.9.4812-4817.2002. View

14.

Moore T, Ekworomadu C, Eko F, Macmillan L, Ramey K, Ananaba G . Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis. 2003; 188(4):617-24. DOI: 10.1086/377134. View

15.

Verthelyi D, Klinman D . Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol. 2003; 109(1):64-71. DOI: 10.1016/s1521-6616(03)00202-x. View

16.

Berry L, Hickey D, Skelding K, Bao S, Rendina A, Hansbro P . Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun. 2004; 72(2):1019-28. PMC: 321610. DOI: 10.1128/IAI.72.2.1019-1028.2004. View

17.

Dong F, Pirbhai M, Zhong Y, Zhong G . Cleavage-dependent activation of a chlamydia-secreted protease. Mol Microbiol. 2004; 52(5):1487-94. DOI: 10.1111/j.1365-2958.2004.04072.x. View

18.

Dong F, Su H, Huang Y, Zhong Y, Zhong G . Cleavage of host keratin 8 by a Chlamydia-secreted protease. Infect Immun. 2004; 72(7):3863-8. PMC: 427399. DOI: 10.1128/IAI.72.7.3863-3868.2004. View

19.

Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan R, Krieg A . Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004; 72(8):4494-502. PMC: 470634. DOI: 10.1128/IAI.72.8.4494-4502.2004. View

20.

Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y . Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984; 72(4):955-62. View